NeuBase Therapeutics’ $46 Million Shares Offering

Wilmer Cutler Pickering Hale and Dorr LLP advised the underwriters on the deal.NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now